HR 3 | Radio-Telethon Day 1 continues!
This hour: Maddie Squire, 26, Breast Cancer Survivor, with Erica Mayer, MD, Dir., Patient & Family Programs, The Jimmy Fund Clinic, Dana-Farber Cancer Institute; Lisa Scherber, Dir., Patient & Family Programs, The Jimmy Fund Clinic, Dana-Farber Cancer Institute; Peter Chow, 68, Stage IV Lung Canc...
Maddie Squire, 26, Breast Cancer Survivor, with Erica Mayer, MD, Dir., Patient & Family Programs, The Jimmy Fund Clinic, Dana-Farber Cancer Institute
Maddie Squire, 26, Breast Cancer Survivor, with Erica Mayer, MD, Dir., Patient & Family Programs, The Jimmy Fund Clinic, Dana-Farber Cancer Institute, both join Jones & Keefe live from the 2026 WEEI/NESN Jimmy Fund Radio-Telethon!
Conference Highlights: New Breast Cancer Research from ASCO 2026
In this Breast Cancer Breakthroughs series, Harold Burstein, MD, PhD, speaks with breast cancer experts from Dana-Farber about new research presented at the 2026 ASCO Annual Meeting.
Topics include advances in early and metastatic breast cancer, new treatment approaches, clinical trial results, f...
Oral SERDs for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Aditya Bardia and Dr Erica Mayer, including the following topics:
Introduction: How Selective Estrogen Receptor Degraders (SERDs) Work (0:00)
Second-Line Treatment for Metastatic Breast Cancer (16:01)
First-Line Therapy for Metastatic Disease (33:19)
Adjuvant ...
Camizestrant + CDK 46i FDA Approval in Hormone Receptor Positive Breast Cancer SERENA-6
Welcome to another episode of the Oncology Brothers! In this episode, we dived into the recent FDA approval of camizestrant for the treatment of hormone receptor–positive metastatic breast cancer, based on the SERENA-6 trial.
We welcomed Dr. Erica Mayer, a breast medical oncologist from the Dana...
ASCO 2026 Highlights Panel Discussion
In this episode of Breast Cancer Insights, Harold Burstein, MD, PhD, speaks with Dana-Farber breast cancer experts Sara Tolaney, MD, MPH; Nancy Lin, MD; Erica Mayer, MD, MPH; and Jennifer Ligibel, MD, about important breast cancer research presented at the 2026 ASCO Annual Meeting.
The experts di...
Episode 65: The evERA Breast Cancer Trial
Recently published in NEJM, this trial made significant noise as it may be the stepping stone to changing how we manage a subset of breast cancer.Dr. Erica Mayer, the first author and lead investigator, joined Healthcare Unfiltered EXPRESS to share all you must know about the trial and potential ...
Hormone Receptor-Positive Localized Breast Cancer — A Grand Rounds Activity
Featuring an interview with Dr Erica Mayer, including the following topics:
Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00)
Investigator Survey Results on Risk Assessment and Genomic Assays (20:07)
Adjuvant CDK4/6 Inhibitors for...
Hormone Receptor-Positive Localized Breast Cancer — A Grand Rounds Activity
Featuring an interview with Dr Erica Mayer, including the following topics:
Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00)
Investigator Survey Results on Risk Assessment and Genomic Assays (20:07)
Adjuvant CDK4/6 Inhibitors for...
Hormone Receptor-Positive Localized Breast Cancer — A Grand Rounds Activity
Featuring an interview with Dr Erica Mayer, including the following topics:
Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00)
Investigator Survey Results on Risk Assessment and Genomic Assays (20:07)
Adjuvant CDK4/6 Inhibitors...
